<- Go Home
Cardiol Therapeutics Inc.
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38, a novel subcutaneously administered drug formulation of cannabidiol for the treatment of heart failure. Cardiol Therapeutics Inc. was incorporated in 2017 and is headquartered in Oakville, Canada.
Market Cap
CAD 207.9M
Volume
119.3K
Cash and Equivalents
CAD 26.1M
EBITDA
-CAD 35.8M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
N/A
Profit Margin
N/A
52 Week High
CAD 3.23
52 Week Low
CAD 1.23
Dividend
N/A
Price / Book Value
8.58
Price / Earnings
-5.31
Price / Tangible Book Value
8.58
Enterprise Value
CAD 182.0M
Enterprise Value / EBITDA
-5.08
Operating Income
-CAD 35.9M
Return on Equity
190.18%
Return on Assets
-90.92
Cash and Short Term Investments
CAD 26.1M
Debt
CAD 107.0K
Equity
CAD 24.0M
Revenue
N/A
Unlevered FCF
-CAD 15.5M
Sector
Pharmaceuticals
Category
N/A